Retatrutide cholesterol effects — need advice

Dr.BariatricHTX said:

The glucagon component looks paradoxical and is not.

Careful with treating an unchanged LDL-C as a failure. If ApoB and triglycerides both fell, the particle picture improved regardless of what the calculated LDL says.

Adding the numbers, since they settle part of this. For anyone tracking the class: GLP-1 alone gets you appetite, GLP-1 plus GIP adds tolerability and lipid handling, and adding glucagon adds expenditure and liver-fat reduction. Each addition also adds a receptor system that can generate side effects.

Worth separating that from retatrutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

TirzTom said:

Careful with treating an unchanged LDL-C as a failure.

Advanced lipoprotein testing on the lipid panel — going beyond standard lipid panel:

The shift from small dense to large buoyant LDL is particularly important — it represents a fundamental change in the atherogenic profile.

Following on from jason_sac26 — and this may be the naive question:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

Closing the loop on my own question.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.